Opinion|Videos|August 14, 2024
Efficacy and Safety of 2L therapies for RS+ patients
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series
- Please discuss the efficacy and safety findings from studies supporting currently available 2L therapies and how they inform your treatment choices for patients who are RS positive:
- IMerge (Platzbecker et al. Lancet 2024) (Santini et al. EHA 2024, Abstr. S184)
- MEDALIST (Fenaux et al. NEJM 2020) (Santini et al. ASH 2023, Abstr. 915)
- Please describe the similarities/differences between the two trials regarding the data related to defining transfusion independence.
- Compare/contrast the data from IMerge and MEDALIST for patients based on whether they received (a) 2 to <4 units, (b) 4 to <6, or (c) ≥6 units every 8 weeks
Advertisement
Related to this article
Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5